FDA grants accelerated approval for Bayer lung cancer drug sevabertinib in first-line HER2-mutant NSCLC
Reuters2026/09/09 18:23- FDA granted accelerated approval for Bayer’s sevabertinib as first-line therapy in adults with advanced HER2-mutant non-squamous NSCLC.
- Clearance covers tumors with HER2/ERBB2 TKD activating mutations identified by an FDA-authorized test.
- Decision relied on SOHO-01 data in 69 treatment-naïve patients, showing a 75% objective response rate.
- Ongoing Phase III SOHO-02 trial could determine continued approval.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan resumes coverage of Lithium Americas (LAC.US) and upgrades to "Overweight", target price of $6.
Lithium Americas (LAC.US) shares rose 6% on Wednesday after JPMorgan resumed coverage and raised its rating to "Overweight" with a target price of $6.
Charlie Hospital Semarang says no material information behind share-price volatility
Venteny Fortuna International files corrected annual public expose materials
Abu Dhabi Mubadala Strategic Investment in Luckin Coffee Explained: Transfer of Preferred Shares by New and Old Funds, Transaction Size Around 1 billion USD
The beneficial ownership of Dachen remains unchanged.
Crypto prices
More
